Feasibility and Acceptability of a Strategy Deploying Multiple First-Line Artemisinin-Based Combination Therapies for Uncomplicated Malaria in the Health District of Kaya, Burkina Faso

Author:

Kaboré Jean Moïse Tanga123ORCID,Siribié Mohamadou1,Hien Denise1ORCID,Soulama Issiaka14ORCID,Barry Nouhoun1,Baguiya Adama4,Tiono Alfred B.1,Burri Christian23ORCID,Tchouatieu André-Marie5,Sirima Sodiomon B.1ORCID

Affiliation:

1. Groupe de Recherche Action en Santé (GRAS), Ouagadougou 10248, Burkina Faso

2. Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland

3. University of Basel, Petersplatz 1, 4001 Basel, Switzerland

4. Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou 7192, Burkina Faso

5. Medicines for Malaria Venture (MMV), 1215 Geneva, Switzerland

Abstract

(1) Background: Effective malaria case management relies on World Health Organization (WHO) recommended artemisinin-based combination therapies (ACTs), but partial resistance to artemisinin has emerged and is spreading, threatening malaria control and elimination efforts. The strategy of deploying multiple first-line therapies (MFT) may help mitigate this threat and extend the therapeutic life of current ACTs. (2) Methods: A district-wide pilot quasi-experimental study was conducted, deploying three different ACTs at the public health facility (PHF) level for uncomplicated malaria treatment from December 2019 to December 2020 in the health district (HD) of Kaya, Burkina Faso. Mixed methods, including household and health facility-based quantitative and qualitative surveys, were used to evaluate the pilot programme. (3) Results: A total of 2008 suspected malaria patients were surveyed at PHFs, of which 79.1% were tested by rapid diagnostic test (RDT) with 65.5% positivity rate. In total, 86.1% of the confirmed cases received the appropriate ACT according to the MFT strategy. The adherence level did not differ by study segment (p = 0.19). Overall, the compliance level of health workers (HWs) with MFT strategy was 72.7% (95% CI: 69.7–75.5). The odds of using PHF as the first source of care increased after the intervention (aOR = 1.6; 95% CI, 1.3–1.9), and the reported adherence to the 3-day treatment regimen was 82.1%; (95% CI: 79.6–84.3). Qualitative results showed a high acceptance of the MFT strategy with positive opinions from all stakeholders. (4) Conclusions: Implementing an MFT strategy is operationally feasible and acceptable by stakeholders in the health systems in Burkina Faso. This study provides evidence to support the simultaneous use of multiple first-line artemisinin combination therapies in malaria-endemic countries such as Burkina Faso.

Funder

Medicines for Malaria Venture

Publisher

MDPI AG

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology

Reference40 articles.

1. World Health Organization (2022). World Malaria Report 2022.

2. Ministère de la Santé (2022, May 21). Secrétariat Général, Direction Générale des Etudes et des Statistiques Sectorielles, Burkina Faso. Annuaire Statistique 2020, Available online: https://www.sante.gov.bf/fileadmin/user_upload/storages/annuaire_statistique_ms_2020_signe.pdf.

3. The public health impact of chloroquine resistance in Africa;Trape;Am. J. Trop. Med. Hyg.,2001

4. Global Partnership to Roll Back Malaria (2023, February 14). Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation, 4–5 April 2001, Available online: https://apps.who.int/iris/handle/10665/66952.

5. Current and emerging strategies to combat antimalarial resistance;Rasmussen;Expert. Rev. Anti. Infect. Ther.,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3